These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24141191)

  • 1. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.
    Xu XJ; Tang YM
    Cancer Lett; 2014 Feb; 343(2):172-8. PubMed ID: 24141191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
    Chmielewski M; Kopecky C; Hombach AA; Abken H
    Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
    Gross G; Eshhar Z
    Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.
    Zhang E; Xu H
    J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
    Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
    Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
    Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.
    Cartellieri M; Bachmann M; Feldmann A; Bippes C; Stamova S; Wehner R; Temme A; Schmitz M
    J Biomed Biotechnol; 2010; 2010():956304. PubMed ID: 20467460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
    Shi H; Sun M; Liu L; Wang Z
    Mol Cancer; 2014 Sep; 13():219. PubMed ID: 25241075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
    Magee MS; Snook AE
    Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management Principles Associated With Cytokine Release Syndrome.
    Baer B; Dudley CV; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
    Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J
    J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment.
    Van Schandevyl S; Kerre T
    Acta Clin Belg; 2020 Feb; 75(1):26-32. PubMed ID: 30422748
    [No Abstract]   [Full Text] [Related]  

  • 19. Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report.
    Wang LX; Chen X; Jia M; Wang S; Shen J
    Medicine (Baltimore); 2018 Apr; 97(16):e0455. PubMed ID: 29668614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine signaling in chimeric antigen receptor T-cell therapy.
    Kagoya Y
    Int Immunol; 2024 Feb; 36(2):49-56. PubMed ID: 37591521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.